

# CURRICULUM VITAE

**Name:** Reena Nair

**Gender:** Female

**Date of Birth:** 09/11/1960

**Designation:** Senior Consultant, Department of Clinical Hematology, TATA Medical Centre, Kolkata

## **Educational Qualification:**

<b>1988</b>	:	Doctor of Medicine (MD), Postgraduate degree in Internal Medicine, from Bombay University.
<b>1983</b>	:	Bachelor of Medicine and Bachelor of Surgery(MB BS) Graduate degree, from Bombay University, with first class honours and distinction in Human Anatomy

## **Details of Training and Experience:**

Internship	:	From January 1984 to December 1984, at the Goa Medical College Hospitals, Goa.
Junior Residency	:	From March 1985 to March 1988, in the Department of Medicine at the Goa Medical College Hospital, Goa.
Registrar	:	March 1988 to December 1988, Intensive Care Unit, Department of Medicine, PD Hinduja National Hospital, Bombay.
Junior Residency	:	January-December 1989, Department of Medical Oncology, Tata Memorial Hospital, Bombay.
Senior Residency	:	January to December 1990, Department of Medical Oncology, Tata Memorial Hospital, Bombay.
Research Fellow	:	January 1992 to June 1994, Department of Medical Oncology, Tata Memorial Hospital, Bombay.
Clinical Observer	:	July 1994 to September 1994, Department of Clinical Oncology, Royal Postgraduate Medical School, Hammersmith Hospital, London.
Pool Officer – (Research Associate)	:	November 1994 to July 1996, Department of Medical Oncology, Tata Memorial Hospital, Mumbai.

## **Clinical Appointments:**

Lecturer and Assistant Medical Oncologist	:	August 1996 to October 2001, Department of Medical Oncology, Tata Memorial Hospital, Mumbai
Associate Professor & Medical Oncologist	:	November 2001 to November 2004, Department of Medical Oncology, Tata Memorial Hospital, Mumbai
Additional Professor & Medical Oncologist	:	November 2004 to November 2008, Department of Medical Oncology, Tata Memorial Hospital, Mumbai
Professor and Medical Oncologist	:	November 2008 to July 2012, Department of Medical Oncology, Tata Memorial Hospital, Mumbai

Convener – Hemato Lymphoid (-Adult)	:	January 2009 onwards to March 2012, Department of Medical Oncology, Tata Memorial Hospital, Mumbai
Senior Consultant, Clinical Hematology and Medical Oncology		October 2012 onwards, Tata Medical Center, Kolkata

### Administrative Appointment

S. No	Office held and organization
1.	Member, Executive committee: Mumbai Hematology Group 1997.
2.	Treasurer, Indian Oncology Study Group, Mumbai 2001-2012.
3.	Joint Secretary, Mumbai Hematology Group 2004.
4.	Member (co-opted), Executive committee, Indian Society of Medical & Pediatric Oncology 2004 -2006.
5.	Treasurer: Indian Breast Group 2004-2006
6.	Founding Member: Myeloma India Foundation 2004
7.	Indian APL Study Group: Member 2004 onwards
8.	Scientific Committee Member, Tata Memorial Hospital, 2004 – 2006.
9.	Human Ethics Committee Member, Tata Memorial Hospital, 2007- 2011.
10.	Founder Member, Developing countries task force, Breast International Group, 2008.
11.	Founder Member “Registry for epidemiology end results and analysis in lymphomas (REEA-L), Indian Oncology Study Group 2009.
12.	Invited Faculty, Australian and Asia Pacific Clinical Oncology Research Development (ACORD). September 2010, 2012 and 2014.
13.	Invited Member, Scientific Advisory Committee, National Institute of Immuno- Hematology, ICMR, KEM Hospital, Mumbai, June 2011.
14.	Invited member of the International Data Safety Monitoring Committee (DSMC), for Sandoz Biopharmaceuticals, Germany, 2011-2013.
15.	Steering Committee member and Invited Faculty, Australian and Asia Pacific Clinical Oncology Research Development (ACORD), September 2012- September 2014.
16.	Institute Review Board Member, ACTREC, Tata Memorial Centre, 2012.
17.	Executive Committee member and Invited Faculty, Australian and Asia Pacific Clinical Oncology Research Development (ACORD), September 2014- September 2016.
18.	Invited member of the International Data Safety Monitoring Committee (DSMC), for Sanofi Pharmaceuticals, 2015-2017.

### Memberships

S. No	Year	Role and organization
1.	1995	Mumbai Hematology Group: Life member
2.	1997	Indian Society of Medical & Pediatric Oncology: Life Member.
3.	1998	Indian Breast Group: Life Member.
4.	2004	European Society of Medical Oncology (ESMO): Member 2004 - 2012
5.	2004	Scientific Committee Member, Tata Memorial Hospital, 2004 – 2006
6.	2004	Myeloma India Foundation: Founder Member 2004
7.	2004	Indian APL Study Group: Member 2004 onwards.
8.	2005	American Society of Clinical Oncology (ASCO): Member 2005 -2012
9.	2007	Indian Oxford (INDOX) Trials Group- Principle Investigator for Hemato- Lymphoid malignancies, 2009 - 2014.
10.	2011	American Society of Hematology (ASH): Member 2011 - 2012

### DM TEACHER/ THESIS EXAMINER- Medical Oncology

S.No	Year	Institutes
1.	2005 onwards	Department of Medical Oncology, Tata Memorial Centre: Have been Guide to four students, Examiner, as well as Convener of examinations.
2.	2008	Department of Medical Oncology, Gujarat Cancer Research Institute, Ahmedabad.
3.	2011/ 2012	Department of Medical Oncology, Examiner at All India institute of Medical Sciences, Rotary Cancer Institute, New Delhi.
4.	2012	Department of Medical Oncology, Cancer Institute, Adiyar Chennai (COPE for all India DM candidates) - Faculty.
5	2015	Department of Medical Oncology, Thesis Reviewer, Shere Kashmir Medical College, Srinagar Jammu & Kashmir.

### Clinical Research Projects - Investigator Initiated Clinical Trials

No.	Title of the approved trial
1.	Phase II trial of amifostene in myelodysplastic syndrome - Department Protocol. <b>Trial Co-ordinator.</b> Completed in <b>March 1998</b>
2.	Phase III trial of BEP chemotherapy versus VIP chemotherapy in testicular germ cell tumours - Department Protocol. <b>Trial Co-ordinator.</b> Completed in <b>August 1998.</b>
3.	UKCCCR Adjuvant Endocrine Therapy and Chemotherapy in women with Early Breast Cancer (ABC) Trial: Approval 1998, Accrual completed <b>Sept 2000. Co-investigator &amp; later Principal Investigator</b>
4.	Alternating Triple Therapy Regimen in Adult Aggressive Lymphomas (B-Cell Type): Correlation with distinct biologic entities. - Department Protocol 1998 → approved by the Indian Council Medical Research (ICMR). Accrual completed <b>April 2003. Co-investigator &amp; later Principal Investigator</b>
5.	All Trans-Retinoic Acid along with Daunomycin followed by Arsenic Trioxide as Sequential Therapy in

	Acute Promyelocytic Leukaemia: Correlation of hematologic and cytogenetic remission. Department Audit. Accrual completed <b>July 2000. Co-investigator &amp; later Principal Investigator</b>
6.	Analysis of immunophenotype, IgH chain variable Intramural N region genes and chemokine SDF-1/CXCR4 interaction in B – Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Non-Hodgkin’s Lymphoma, an Intramural TMC Grant. <b>Co-investigator</b> . Approved for Intra-mural funding 2002. Accrual completed <b>2003</b>
7.	EORTC Protocol No. 10951 (Amendment n°2) titled as “Randomized phase II - III study in first line hormonal treatment for metastatic breast cancer with EORTC Exemestane or Tamoxifen in Postmenopausal patients”. <b>Co-investigator &amp; later Principal Investigator</b> . Completed follow up completed in <b>May 2004</b>
8.	Molecular Remission with Arsenic trioxide in acute promyelocytic leukemia. Indian APML Study Group Trial sponsored by Department of Biotechnology (DBT). <b>Co-Principal Investigator at TMH</b> . Ethics Committee approval 2005, Accrual completed 2008. Follow up completed 2012.
9.	Timing of systemic chemotherapy in isolated loco regional recurrence in patients with Breast cancer. (Approved by Ethics Committee Aug 2005). <b>Principal Investigator</b> . Sponsored partly by Women’s Cancer Initiative (WCI). Study closed in 2010.
10.	A prospective study of the fungal serology in the early diagnosis of fungal infections in patients of acute leukemia, high grade non Hodgkin’s lymphoma, hematopoietic stem cell transplantation presenting with infection/ fever and high risk neutropenia. Ethics Committee approval March 2006. Sponsored by Pfizer (unconditional research grant). <b>Principal Investigator</b>
11.	Application of FDG PET and molecular profiling for risk stratification of diffuse large B cell non Hodgkins Lymphoma in different ethnic populations. International Atomic Energy Agency (IAEA). Ethics Committee Approval June 2008, enrollment completed June 2011. <b>Principal Investigator</b>
12.	Establishment of Registry for Epidemiology and End Results Analysis in Lymphomas (REEA-L), Mumbai. Sponsored by Dr Reddy’s Laboratory (Unrestricted Educational Grant) Ethics Committee Approval June 2010. <b>Principal Investigator</b>
13.	Establishment of National Lymphoma Registry (R-Lymph 20). Sponsored by Roche (Unrestricted Research Grant). Ethics Approval June 2011. <b>Principal Investigator</b>
14.	Comparison of efficacy and safety of Rituximab (Mabthera) and its biosimilar (Reditux) in diffuse large B cell lymphoma (DLBCL) patients treated with chemo immunotherapy: A retrospective analysis. Ethics Approval July 2011. <b>Principal Investigator – (student thesis)</b> .
15.	Treatment results of advanced stage Hodgkin’s lymphoma: A retrospective study. Ethics Approval July 2011. <b>Principal Investigator- (student thesis)</b> .
16.	An observational bioequivalence study of two Rituximab formulations in patients with diffuse large B cell lymphomas. Ethics Approval Sept 2011. <b>Co- Investigator</b>
17.	Patient generated Subjective Global assessment to predict early outcomes in Lymphoma. Ethics Approval Sept 2011. <b>Principal Investigator- (student thesis)</b> .
18.	Development of a registry to assess the demography, cytogenetic profile and treatment outcomes of patients with multiple myeloma- Mumbai Myeloma Program. Ethics Approval March 2012. <b>Co-Investigator</b> .
19.	Immuno-histochemistry and Molecular profiling of large B-cell lymphomas with respect to double hit lymphomas. Ethics committee approval awaited 2015. <b>Co- Principal Investigator</b>

#### Sponsored Clinical Trials

S.No.	
1.	Phase III multicentre trial of Tamoxifen versus Droloxefene in the management of advanced and recurrent breast cancers sponsored by Pfizer. <b>Trial Co-ordinator</b> . Completed in <b>September 1998</b> .

2.	Evaluation of the effect of early intervention with epoetin alfa on anaemia in cancer patients receiving platinum-based chemotherapy sponsored by Johnson & Johnson. <b>Co-Investigator</b> . Completed in <b>December 1998</b>
3.	Phase III multicentre trial of idoxifene 40 mg/ day versus tamoxifen 20 mg/ day as first line hormonal therapy of metastatic breast cancer in post menopausal women sponsored by SmithKline Beecham. <b>Co-Investigator</b> Completed in <b>September 1999</b>
4.	Phase III multicentre trial of TLC D-99 doxorubicin and cyclophosphamide versus doxorubicin and cyclophosphamide in the treatment of metastatic breast cancer sponsored by Quintiles Spectral India Ltd. <b>Trial Co-ordinator</b> . Completed in <b>March 1999</b>
5.	Phase III multicentre trial of docetaxel in the dose of 100mg and 75mg in treatment of advanced breast cancers sponsored by Rhone Poulenc (Rorer). <b>Trial Co-ordinator</b> . Completed in <b>August 1998</b>
6.	A double-blind randomized placebo-controlled parallel-group study looking at the effect of intranasal IM 862 on the overall tumour response rate as an add-on to conventional chemotherapy in Breast Cancer sponsored by Nicholas Piramal India Ltd. Co-Investigator. Completed in <b>Sept 2000</b> . <b>Co-investigator</b>
7.	A Single-blind Randomized Phase 3 Trial of MTA plus Cisplatin versus Cisplatin in Patients with Malignant Pleural Mesothelioma sponsored by Eli-Lilly Ranbaxy Ltd. Accrual completed in October 2000. Follow up completed in <b>May 2004</b> . <b>Co-investigator &amp; later Principal Investigator</b>
8.	Protocol CA002-0LD : Multicentre Study of a Cremophor® - Free, Protein Stabilized, Nanoparticle Formulation of Paclitaxel (ABI-007) in-Patients with Stage IV Metastatic Breast Cancer' sponsored by Quintiles Spectral (I) Ltd. Accrual completed in October 2001. Follow up completed in <b>May 2004</b> . <b>Co-investigator</b>
9.	Protocol B9E-MC-S197 titled as Randomized Phase II Trial of Gemcitabine combined with a Taxane for Metastatic Breast Cancer. Completed in <b>Sept 2003</b> sponsored by Eli Lilly. Co-Investigator. (Abstract presented at ASCO 2004). <b>Co-investigator</b>
10.	A Multicentric Phase I Clinical and Pharmacological Study of DRF 1042, a Novel Camptothecin Analog given orally in Adult Patients with Refractory Solid Tumors Approved by the Ethics Committee in <b>November 2001</b> . Sponsored By Dr. Reddy's Research Foundation. <b>Principal Investigator</b>
11.	Phase 3 trial of LY900003 PLUS Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in patients with advanced, previously untreated Non Small Cell Lung Cancer Sponsored by Eli Lilly. Approved by the Ethics Committee in <b>November 2001</b> . <b>Principal Investigator</b>
12.	Protocol Number BO16216E/H2223g: A randomized, controlled, open label study to evaluate the efficacy and safety of Herceptin® (trastuzumab) in combination with the oral aromatase inhibitor Arimidex® (anastrozole) compared with Arimidex® alone as first and second line treatment administered to postmenopausal, hormone receptor positive (ER+ve and/or PR+ve) patients with HER2 overexpressing metastatic breast cancer, sponsored by Roche. Approved <b>June 2003</b> . Accrual completed Jan 04. Follow up completed May 2005. <b>Co-investigator &amp; later Principal Investigator</b>
13.	A randomized trial of Pivanex plus Docetaxel or Docetaxel Monotherapy resistant advanced non-small cell Carcinoma of the Lung (NSCLC)", sponsored by Quintiles Spectral India. <b>Co-investigator</b> . Approved in <b>Sept 2003</b> . Accrual completed in April 2004. <b>Follow up</b> completed 2004. <b>Co-investigator &amp; later Principal Investigator</b>
14.	A phase III Study (Tesmififene) Combined with epirubicin and Cyclophosphamide versus epirubicin and Cyclophosphamide alone as first line treatment in metastatic or Recurrent Breast Cancer. Scientific Committee approval <b>June-04</b> . Pharm-Olam International (UK) Ltd. Accrual completed Sept 2005. Trial completed in 2007. <b>Principal Investigator</b>
15.	A randomized, double blind, parallel group, multicentre, Phase III study comparing the efficacy and tolerability of fulvestrant (faslodex) 500 mg with fulvestrant (faslodex) 250 mg in postmenopausal women with estrogen receptor positive advanced breast cancer progressing or relapsing after previous endocrine therapy, sponsored by Quintiles Spectral India. Approved by Ethics Committee Aug 2005. Accrual started Jan 2006. Trial completed in 2010. <b>Principal Investigator</b> .
16.	A phase 3 randomized, double-blind study of oral CCI-779 administered in combination with letrozole versus letrozole alone as first line hormonal therapy in postmenopausal women with locally advanced

	or metastatic breast cancer. Approved by Ethics Committee Nov 2005. Accrual started Jan 2006. Study close out Nov 2006. <b>Principal Investigator.</b>
17.	A phase III randomized controlled trial of myocet, trastuzumab and paclitaxel versus trastuzumab and paclitaxel for first line therapy of metastatic breast cancer. Study protocol STM01-102. Approved by Ethics Committee Oct 2006. Accrual completed in Nov 2007. Follow up ongoing 2011. <b>Principal Investigator.</b>
18.	Efficacy and safety of SIIL recombinant Human Granulocyte colony stimulating factor, r-PEG –Hu GCSF, PEG SILGRASTIM in the correction of neutropenia in patients with solid tumor/ lymphomas undergoing myelosuppressive chemotherapy when compared to Filgrastim. Approved by Ethics Committee Oct 2006. Accrual started in Nov 2006. Trial close out in Aug 2008. <b>Principal Investigator.</b>
19.	Protocol No 16835-D An open label randomized phase II study of two different dosing regimens of capecitabine in combination with intravenous docetaxel (q3w) in patients with locally advanced and/or metastatic breast cancer. Approval by Ethics Committee March 2007). Accrual started in Apr 2007. <b>Status:</b> Completed. <b>Principal Investigator.</b>
20.	Project EGF 105485: A randomized, double blind, multicenter, placebo controlled study of adjuvant Lapatinib in women with early stage ErbB2 overexpressing breast cancer. Approval by Ethics Committee in April 2007. Accrual: Completed. Follow up: Ongoing. <b>Principal Investigator.</b>
21.	Phase III study of vinflunine plus gemcitabine versus paclitaxel plus gemcitabine in patients with unresectable, locally recurrent of metastatic breast cancer after prior anthracycline based adjuvant chemotherapy” <b>Project No. 429 Principal Investigator</b> Ethics Approval: 10th Aug '07 <b>Status:</b> Stopped for excessive toxicity
22.	A phase 3 clinical study to investigate the prevention of relapse in lymphoma using Daily Enzastaurin ( <b>Project No: 578</b> ) Ethics Approval: 31.7.08, <b>Status:</b> Closed. <b>Principal Investigator.</b>
23.	Project (ALTTO EGF106708) a randomized, Multicentre, Open-label, Phase III study of adjuvant Lapatinib, trastuzumab, their sequence and their combination in patients with HER2/ ErbB2 positive primary breast cancer. Ethics approval Sept 2008 <b>Status:</b> Ongoing. <b>Principal Investigator.</b>
24.	Single-arm, open-label, multicenter Phase II study to evaluate the efficacy and safety of P276-00 in patients with relapsed and/or refractory mantle cell lymphoma. <b>EC Approval:</b> 18.12.09 <b>Status:</b> Closed. <b>Principal Investigator.</b>
25.	A Randomized, Multi-center, Double- blind, Parallel Group study to compare the pharmacokinetics, Pharmacodynamics, Safety and Efficacy of two anti- CD 20 monoclonal antibodies in combination with GHOP in patients with CD 20 – positive Diffuse Large B-Cell Lymphoma. [Protocol ID : RI-02-001]. <b>EC Approval:</b> 03.12.13 <b>Status:</b> Ongoing. <b>Principal Investigator.</b>
26.	A multicenter, Retrospective medical record review study to describe real-world treatment patterns and safety among patients receiving rituximab [Mabthera or Reditux] to treat B-Cell non Hodgkin Lymphoma in India. [Protocol ID : RI-02-002]. <b>EC Approval:</b> 11.08.14 <b>Status:</b> Completed. <b>Principal Investigator.</b>
27.	Reditux Registry to compare Effectiveness, Safety, and Resource Utilization of Reditux vs the reference Medicinal product to treat Diffuse Large B –Cell lymphoma and Chronic Lymphatic Leukemia in Routine Clinical Practice [Protocol ID : RI-02-003]. <b>EC Approval:</b> 09.07.15 <b>Status:</b> Ongoing. <b>Principal Investigator.</b>

#### **Publications- Original papers**

1. **Nair R.** Ulcerative colitis: dissertation for MD Medicine, Bombay University, Bombay. (MD Thesis)
2. Athale UH, **Nair R**, Kadam P, Pai SK, Advani SH. Acute leukaemia in Down's syndrome. Indian Paediatrics. 1990; 27(1): 3-5.
3. Athale UA, **Nair R**, Iyer R, Nair CN, Kadam P, Advani SH. Chronic myelomonocytic leukaemia: an analysis of fourteen consecutive cases. J Assoc Phys India. 1991; 39(5): 390-3.

4. **Nair R**, Athale UA, Iyer RS, Nair CN, Pai SK, Kurkure PA, Kadam PR, Advani SH. Childhood myelodysplastic syndromes: clinical features, cytogenetics and prognosis. *Indian J Paediatrics*. 1992; 59(4): 443-8.
5. **Nair R**, Kane SV, Borges A, Advani SH. Giant cell fibroblastoma. *J Surg Oncol* 1993; 53(2):136-9.
6. **Nair R**, Krishnamurthy s, Advani SH. Maxillary extragonadal germ cell tumor: a case report. *Ind J Cancer* 1993; 30: 202-204.
7. **Nair R**, Iyer RS, Nair CN, et al. Myelodysplastic syndromes: a clinical and pathological analysis of 88 patients. *Indian J Cancer* 1993; 30: 169-175.
8. **Nair R**, Kane SV, Borges A, Advani SH. Giant cell fibroblastoma. *J Surg Oncol* 1993; 53 (2): 136-139.
9. **Nair R**, Advani SH. Management of acute leukaemia: present concept. *Indian Pediatr* 1993; 30: 589-591.
10. **Nair R**, Pathak AB, Saikia T, Advani SH. Bone marrow rescue using recombinant human GM-CSF: a report of two cases. *Indian J Hematol* 1993; 11: 18-21.
11. **Nair R**, Gopal R. The treatment of intermediate and high grade non Hodgkin's lymphoma in adults. *Indian J Hematol Blood Trans* 1994; 12: 152-156.
12. **Nair R**, Pai SK, Saikia TS, Nair CN, Kurkure PA, Gopal R, Sampat MS, Advani SH. Malignant germ cell tumor in childhood. *J Surg Oncol* 1994; 56: 186-190.
13. **Nair R**, Advani SH. Pediatric Hemato-oncology in India. *Pediatric Hematol Oncol* 1994; 11: 129-134.
14. Gopal R, **Nair R**, Saikia TK, et al. Modified MACOP-B chemotherapy. *J Assoc Phys India* 1994; 42: 781-784.
15. Kadam P, Dadabhoy K, Bhise A, Athale U, **Nair R**, Advani SH. Chromosome investigations and clinical outcome in patients with myelodysplastic syndrome. *Ind J Med Res* 1995; 101: 163-169.
16. Advani H Suresh, **Nair Reena**. Medical Emergencies in Oncology. *Nat. Med J* 1995; 8: 273-276
17. Gauri K, Advani SH, Nair CN, Pai SK, Kurkure PA, **Nair R**, Saikia TK, Vege D, Desai PB. Pediatric germ cell tumor: An experience with BEP. *J Ped Hematol/ Oncol* 1995; 17: 318- 324.
18. **Nair Reena**, Gopal R, Saikia K Tapan, Advani H Suresh. MINE Therapy for patients with resistant or relapsed non-Hodgkins lymphoma. *Ind J Med & Ped Oncol* 1996; 17: 90 - 98.
19. **Nair R**, Saikia TK, Gopal R, et al. Low dose cytosine arabinoside in the treatment of myelodysplastic syndrome. *J Assoc Phys India* 1996; 44: 181- 183.
20. Advani SH, Kochupillai V, Lalitha N, Shanta V, Maitreyan V, **Nair Reena**, Banerjee U, Kelkar R, Mukerjee S. Infections in the immunocompromised host: A prospective multicentre survey in patients receiving chemotherapy for acute leukemia. *J Assoc Phys Ind* 1996; 44: 769-773.
21. Bapna A, **Nair R**, Advani SH. The "Retinoic Acid Syndrome" in acute promyelocytic leukemia and its management. *Ind J Med & Ped Oncol* 1997;18: 46-50.
22. **Nair R**, Advani SH. Cancer- Home Care Management. *Current Med J – North zone*, 1998; IV(1): 50-53.
23. **Nair R**, Advani SH : Medical Emergencies in Oncology. *Current Med J - North zone*, 1998; IV (2): 26-32.
24. Advani SH, **Nair R**. Medical Oncology Department, Tata Memorial Hospital. *Ped Hemat Oncol* 1998; 15: 109-115.
25. **Nair R**, Nair CN, Advani SH. All Trans Retinoic Acid with Low dose Cytosine arabinoside in the treatment of Myelodysplastic Syndrome. *Leuk & Lymph* 1998; 29: 187-192.
26. Bapna A, **Nair R**, Saikia TK All trans retinoic acid (ATRA) in Paediatric Acute Promyelocytic Leukemia. *Ped Hemat & Oncol* 1998; 15: 243-248.
27. **Nair R**, Gopal R, Nair N, Saikia TK, Parikh PM, Joshi SR, Soman CS, Muckaden M, Dinshaw KA, Advani SH. Non Hodgkins Lymphoma : A randomised comparison of efficacy and toxicity of epirubicin versus doxorubicin. *Cancer* 1998; 82: 2282 – 2288.
28. Advani SH, **Nair R**, Bapna A, Gladstone B, Kadam P, Saikia TK, Parikh PM, Gopal R, Nair CN. Acute Promyelocytic Leukemia: All-trans Retinoic Acid (ATRA) with Chemotherapy is superior to ATRA alone. *Am J of Hemat* 1999; 60: 87-93.
29. Gupte S, **Nair R**, Naresh KN, Borges AM, Soman CS, Gopal R, Advani SH. MALT Lymphoma of Nasal Mucosa Treated with Antibiotics. *Leuk & Lymph* 1999; 36 : 195-197.

30. Dhiraj Abhyankar, **R Nair**, Hari Menon, Bhupendra Kapur, Suresh Advani. Avascular Necrosis of Head of Femur in a Patient with Acute Promyelocytic Leukemia. *Leuk & Lymph* 2000; 37: 635-637.
31. Kapur B, **Nair R**, Gopal R, Abhyankar D, Naresh K, Laskar S, Muckaden M, Advani S. Primary cardiac Lymphoma – A Case Report. *IJHBT* Dec 2000;18: 94-95.
32. PS Amre,(Kadam), C Baisane, TK Saikia, **R Nair**, H Gawade, SH Advani. Fluorescence in situ hybridization: a highly efficient technique of molecular diagnosis, also a sensitive tool for prediction of future course of disease in patients with myeloid leukemia. *Cancer Gen Cytogen* 2001;131;125-134.
33. Agarwal B, Ramanathan U, Lokeshwar N, **Nair R**, Gopal R, Bhatia K, Naresh KN. Lymphoid Neoplasms in HIV - Positive Individuals in India. *J Acquir Immun Def Syndr* 2002; 29 (2): 181-183.
34. **Reena Nair**, Lokeshwar NM, Myelodysplastic Syndrome (MDS). *Ind J Hemat & Bld Trans* 2002; XX No 3: 73-79.
35. Indumati Ambulkar, **Reena Nair**. Primary Ovarian Lymphoma: Report of Cases and Review of Literature. *Leuk Lymph* 2003; 44 (5): 825-827.
36. Advani SH, **Nair Reena**, et al. Febrile Neutropenia: Indian Guideline 2004.
37. Deshmukh C, Bakshi A, Parikh P, **Nair R**, et al. Primary Non-Hodgkins Lymphoma of the bone: a single institute experience. *Med Oncol* 2004; 21:
38. Biswas g, Khurana R, Bhagwat R, **Nair R**, Banavali SD, Vora A, Parikh PM. Necrotizing fasciitis in Acute lymphoblastic leukemia. *JAPI* 2004; 52: 890.
39. Sharma LM, Biswas G, Rai SS, **Nair R**, Gupta S, Parikh PM. Retroperitoneal plasmacytoma: A case report and review of literature. *Ind J Cancer* 2004; 41: 133- 134.
40. TK Saikia, A Bakshi, R Bhagwat, S Tawde, **R Nair**, CN Nair, PM Parekh. Outcome in adults: A retrospective analysis. *Natl Med J India* 2005; 18: 12-15.
41. Ghanshyam Biswas, Chetan Deshmukh, Ashish Bakshi, **Reena Nair**, Sudeep Gupta, Sumeet Gujral, Purvish M Parekh. Primary Uterine Lymphoma treated by adjuvant chemotherapy after radical surgery. *W JCO* 2005; MS 962549958112431.
42. S Chopra, G Bahl, M Ramadwar, S Ramani, **R Nair**, MA Muckaden, S Laskar. Synchronous mucosa-associated lymphoid tissue (MALT) lymphomas involving bilateral orbits and breasts: a rare clinical entity. *Leuk Lymph* 2005, 46 (8): 1247 – 1250.
43. Ghanshyam Biswas, Parekh M Purvish, **Reena Nair**, Roshni Bhagwat, Kumar Prabhash, Amish Vora, Sudeep Gupta, VR Pai, Hari Menon, PSRK Sastry. Rituximab (Anti CD 20 monoclonal antibody) in Lymphoproliferative Malignancies: Tata Memorial Hospital Experience. *JAPI* 2006; 54: 29-33.
44. Parmar V, Krishnamurthy A, Nadkarni MS, Hawaldar R, Sarin R, Chinoy R, **Nair R**, Thakur M, Jalali R, Gupta S, Shet T, Budrukkar A, Ramani S, Dinshaw KA, Badwe RA. Breast conservation treatment in women with locally advanced breast cancer. *Int J Surg Oncol* 2006; 4: 106-114.
45. Kumar Prabhash, Ghanshyam Biswas, **Reena Nair**, Durgatosh Pandey, Dipen Maru, Aparna Mahajan, Purvish Parekh. Metachronous gastric diffuse large B-cell lymphoma and adenocarcinoma. *Ind J Gastro* 2006; 25: 261- 262.
46. Kei Siong Khoo, Syed Hasan M Zaidi, V Srimunnimit, S Song, **Reena Nair**, Corazon A Ngelangel, Anita Bustam, William H H Reece, Manfred Lehnert. Gemcitabine and split-dose paclitaxel or docetaxel in metastatic breast cancer: a randomized phase II study. *Eur J Oncol* 2006; 42: 1797-1806.
47. Siddhartha Laskar, Mary Ann Muckaden, Gaurav Bahl, Sandeep De, **Reena Nair**, Sudeep Gupta, Ashish Bakshi, Kumar Prabhash, Dipen Maru, Sumeet Gujral, Purvish Parikh, Shyam Kishore Shrivastava, & Ketayun Ardeshir Dinshaw. Primary Non-Hodgkin's Lymphoma of the Nasopharynx: Prognostic Factors and Outcome of 113 Indian Patients. *Leuk Lymph* 2006; 47(10): 2132 – 2139.
48. **The Adjuvant Breast Cancer Trials Collaborative Group**. Polychemotherapy for early Breast Cancer Chemotherapy Randomized Trial. *J Natl Cancer Inst* 2007; 99: 506-515.
49. **The Adjuvant Breast Cancer Trials Collaborative Group**. Ovarian ablation or suppression in premenopausal early breast cancer: results from the International Adjuvant Breast Cancer ovarian ablation or suppression Randomized Trial. *J Natl Cancer Inst* 2007; 99: 516-525.



50. Pranjali K, Prabhash K, Karanth VN, Kane S, **Nair R**, Parikh PM. Umbilical metastasis: an unusual presentation of pancreatic adenocarcinoma. *Ind J Dermat Venerol Lepro* 2007; 73: 199-200.
51. Karanth VN, Pranjali K, Sudeep Gupta, **Reena Nair**, Purvish M Parikh. Cryptosporidiosis in a relapsed case of Hodgkins Disease. *Ind J Med Sci* 2007; 61: 419-421.
52. Siddhartha Laskar, Gaurav Bahl, Mary Ann Muckaden, **Reena Nair**, Sudeep Gupta, Ashish Bakshi, Sumeet Gujral, Tanuja Shet, Shyam Kishore Shrivastava, Ketayun Ardeshir Dinshaw. Primary diffuse large B-Cell lymphoma of the tonsil: is a higher radiotherapy dose required? *Cancer* 2007; 110/4: 816-823.
53. **R Nair**, K Prabhash, M Sengar, A Bakshi, S Gujral, S Gupta, P Parikh. The effect of short –term intensive chemotherapy on reactivation of tuberculosis. *Ann Oncol* 2007; 18: 1234-1245.
54. Sheetal Hingmire, Sachin Hingmire, Ashish Bakshi, Sumeet Gujral, Rajan Badwe, **Reena Nair**. Multiple myeloma mimicking bone metastasis in a patient with carcinoma breast. *Ind J Med/ Ped Oncol* 2008; 29: 53-55.
55. S Gujral, A Agarwal, V Gota, **R Nair**, S Gupta, SK Pai, M Sengar, T Shet, PG Subramanium, M Mukaden, S Laskar. A clinicopathological study of mantle cell lymphoma in a single centre in India. *Ind J Pathol/ Micro* 2008; 51: 315-322.
56. K Prabhash, Vikram GS, **R Nair**, M Sengar, S Gujral, A Bakshi, S Gupta, PM Parikh. Fludarabine in Lymphoproliferative malignancies: A single centre experience. *Natl Med Journal* 2008; 21: 171-174.
57. A Chogule, S Pomlampalli, P Amre, S Shinde, S Banavali, K Prabhash, **R Nair**, PG Subramanium, S Gujral, PM Parikh. Identification of PML/ RARa fusion gene transcripts that showed no t(15;17) with conventional karyotyping and fluorescent in situ hybridization. *Gen & Mol Res* 2009; 8: 1 – 7.
58. Suryaprakash VG, Purandhare NC, Gujral S, Shah S, **Nair R**, Rangarajan V. Positron emission tomography evaluation of primary Hodgkins disease of liver. *Ind J Cancer* 2009; 46: 216- 218.
59. Prabhash K, Medhekar A, Biswas S, Kurkure PA, **Nair R**, Kelkar R. Comparison of *in vitro* activities of ceftazidime, piperacillin-tazobactam, and cefaperazone-sulbactam, and the implication on empirical therapy in patients with cancer. *Ind J Cancer* 2009; 46: 318- 322.
60. Sumeet Gujral, Sunita Polampalli, Y Badrinath, Ashok Kumar, Subramanium PG, **Reena Nair**, Sudeep Gupta, Manju Sengar, Chandrika Nair. Immunophenotyping of mature B-cell non Hodgkin's lymphoma involving bone marrow and peripheral blood: critical analysis and insights gained at a tertiary care cancer hospital. *Leuk Lymph* 2009; 50: 1290- 1300.
61. Shubhada Kane, Aditi Khurana, Gorakh Parulkar, Tanuja Shet, Kumar Prabhash, **Reena Nair**, Sumeet Gujral. Minimum diagnostic criteria for plasmablastic lymphoma of oral/ sinonasal region encountered in a tertiary cancer hospital in the developing country. *J Oral Path* 2009; 38:138-144.
62. Gujral S, Polampalli S, Badrinath Y, Kumar A, Subramanian PG, **Nair R**, Sengar M, Nair C. Immunophenotyping of mature T/NK cell neoplasm presenting as leukemia. *Indian J Cancer*. 2010 Apr-Jun; 47 (2): 189-93.
63. Prabhash K, Medhekar A, Ghadyalpatil N, Noronha V, Biswas S, Kurkure PA, **Nair R**, Kelkar R. Blood stream infections in cancer patients: A single centre experience of isolates and sensitivity pattern. *Ind J Cancer* 2010; 47: 184-188.
64. H Kim Lyerly, Aky P Abernethy, Martin R Stockler, Bogda Koczwar, Zeba Aziz, **Reena Nair**, Lesley Seymour. Need for Global Partnership in cancer care: Perceptions of cancer care researchers attending the 2010 Australia and Asia Pacific Clinical Oncology Research Development Workshop. *J Oncol Practice* 2011; 7: 1-6.
65. **Reena Nair**, Vikas Ostwal, Manju Sengar, Amol Kothekar, Jiggeshu Divetia, Urmila Thate. Lead Intoxication mimicking a malignancy. *Hematol Oncol Stem cell Ther* 2011; 4 (2) 146-147.
66. Manju Sengar, Amol Akhade, **Reena Nair**, Hari Menon, Epari Sridhar, Sumeet Gujral, Tanuja Shet, Siddharth Laskar. Retrospective audit of clinicopathological attributes and treatment outcomes of Adolescent and Young Adults non Hodgkins Lymphoma from a Tertiary Care Centre. *Ind J Med & Pediatr Oncol* 2011; 32:(4) 197-203.

67. Shilpa Gupta, Bhausaheb Bagel, Sumeet Gujral, P G Subramanian, Navin Khattry, Hari Menon, **Reena Nair**. Parenthood in patients of Acute Promyelocytic leukaemia after treatment with Arsenic trioxide - A case series. *Leuk Lymph* 2012; 53:2192-2194.
68. Rakesh Katna, Tanuja Shet, Manju Sengar, Hari Menon, Siddharth Laskar, Prabhash Kumar, Anil D'Cruz, **Reena Nair**. Clinico-Pathological study and outcome analysis of thyroid lymphomas: Experience from a tertiary care centre. *Head & Neck* 2013; 35(2):165-171.
69. Kadam Amre PS, Gadage V, JainH, Nikhaje S, Manju S, Mittal N, Gujral S, **Nair R**. Clinicopathological impact of cytogenetic subgroups in B-cell chronic lymphocytic leukemia: Experience from India. *Ind J Cancer* 2013; 50 (3): 261-267.
70. Shilpa Gupta, **Reena Nair**, Hari Menon, Sumeet Gujral, PG Subramanian. Therapy related acute promyelocytic leukemia following breast cancer treatment- a case report. *JAPI (Sent for publication-Jr No: 244/2011)*
71. Partha S Roy, Shiji John, Sadashiv Karnakal, Sadhana Kannan, Preeti Pawaskar, Jayant Gawande, Bhausaheb Bagal, Navin Khattry, Manju Sengar, Hari Menon, Sumeet Gujral, **Reena Nair**. Comparison of efficacy and safety of Rituximab (Mabthera) and its biosimilar (Reditux) in DLBCL patients treated with chemo immunotherapy: a retrospective analysis. *Ind J of Med & Ped Oncol* 2013; 34 (4) 292- 298.
72. Ramesh Nimmaguda, Raghunandharao Digumarti, **Reena Nair**, Dinesh Bhurani, Vinod Raina, Shyam Agarwal, Shekhar patil, Pabitra Gogai, Subramanian Sundaram, Chanchal Goswami, Shashikant Apte, Srinivas Chakravathy, Anand Pathak. The Epidemiology of lymphomas and treatment outcomes of Diffuse Large B cell Lymphoma: Retrospective Analysis from India. *Ind J of Med & Ped Oncol* 2013; 34 (4) 299-304.
73. Brijesh Arora, Vikram Gota, Hari Menon, Manju Sengar, Reena Nair, Pankaj Patial, Sripad S Banavali. Therapeutic drug monitoring for imatinib. Current status and Indian experience. *Ind J of Med & Ped Oncol* 2013; 34 (3) 224- 228.
74. Laskar Sidharth, Tabassum Khanna, Menon Hari, Sengar Manju Sengar, Sumeet Gujral, Tanuja Shet, Shridhar Epari, Rangarajan Venkatesh, Muckaden Maryann, **Nair Reena**, Banavali Shripad. Radiation therapy for early stage unfavourable Hodgkins Lymphomas: Is dose reduction feasible? *Leuk Lymph* 2013; ID 871631
75. Paul Goss, Kathrin Strasser- Weippi, Bruttany L Lee- Bychkovsky....., **Reena Nair**, .....The Lancet Oncology Commission Challenges to effective cancer control in China, India and Russia. *The Lancet Oncology* 2014; 15(5): 489 – 538.
76. PM Parikh, S Gupta, S Dawood, H Rugo....., **R Nair**, D Doval. ICON 2013: Practical consensus recommendations for hormone receptor – positive HER 2- negative advanced or metastatic breast cancer. *Ind J Cancer* 2014;51(1): 73-79.
77. Juliano Cerci, Tamas Gyorke, Francisca Redonda, Jim P Morris, Claudio Meneghetti, Chirayu Auewarakul, **Reena Nair**, Charity Gorospe, June-key Chung, Isinsu Kuzu, Monica Celli, Rose Ann Padua, Maurizio Dondi, Robert Carr. Prospective International cohort study demonstrates inability of interim PET to predict treatment failure in diffuse large B cell lymphoma. *J Nuc Med* 2014 / 561043
78. Hemant Malhotra, Prantar Chakrabarti, Vikram Mathews, Jina Bhattacharyya, Tulika Seth, K Gayathri, Hari Menon, P G Subramanian, Ajay Sharma, Maitreyee Bhattacharyya, P K Gogoi, **Reena Nair**, SVSS Prasad, MarieTherese, Manipadam , Neelam Varma, AK Vaid, Subhash Varma, MB Agarwal, Shyam Aggarwal, Usha Agarwal. Myeloproliferative Neoplasm Working Group (MPN-WG) consensus

Recommendations for diagnosis and management of Primary Myelofibrosis, Polycythemia Vera and Essential Thrombocythemia. ISMPO, 2014: 03/2015; 36(1). DOI:10.4103/0971-5851.151770

79. Robert Carr, Stefano Fanti, Diana Paez, Juliano Julio Cerci, Tamas Gyorke, Francisca Redondo, Tim P Morris, Claudio Meneghetti, Chirayu Auewarakul, **Reena Nair**, Charity Gorospe, June-Key Chung, Isinzu Kuzu, Monica Celli, Sumeet Gujral, Rose Ann Padua, Maurizio Dondi, Hilal Ozdağ. Prospective International Cohort Study demonstrates inability of Interim PET to predict treatment failure in Diffuse Large B-Cell Lymphoma. *Journal of Nuclear Medicine* 11/2014; 55(12). DOI:10.2967/jnum
80. Neeraj Arora, Indu Arun, Anupam Chakrapani, **Reena Nair**. Classical Hodgkin lymphoma with coexistent plasma cell neoplasm: a case report. *Indian Journal of Pathology and Microbiology* 10/2014; 57(4):656-658. DOI:10.4103/0377-4929.142726
81. Sriram Ravichandran, Monali Gupta, Mayur Parihar, Anupam Chakrapani, **Reena Nair**, Mammen Chandy. Plasma cell leukemia: a management conundrum. *Journal of Postgraduate Medicine* 12/2014; 2014(9):159-61. DOI:10.1093/omcr/omu060.
82. H Kim Lyerly · Maria R Fawzy · Zeba Aziz · **Reena Nair** · C S Pramesh · Vani Parmar · Purvish M Parikh · Rozmin Jamal · Azizunissa Irumnaz · Jun Ren · Martin R Stockler · Amy P Abernethy Regional Variation in Identified Cancer Care Needs of Early-Career Oncologists in China, India, and Pakistan. *The Oncologist* 04/2015; 20(5). DOI:10.1634/theoncologist.2014-0213
83. Hasmukh Jain, Manju Sengar, **Nair Reena**, Siddharth Laskar, Tanuja Shet, Sumeet Gujral, Epari Sridhar. Treatment Results in advanced stage Hodgkins Lymphoma: a retrospective study. *Journal of Postgraduate Medicine* 04/2015; 61(2):88-91. DOI:10.4103/0022-3859.150446
84. Neeraj Arora, Aroonima Mishra, Poonam Santra, **Reena Nair**. Hairy cell leukemia with ascites and coexistent histoplasmosis. *Indian Journal of Pathology and Microbiology* 02/2015; 58(1):125-6. DOI:10.4103/0377-4929.151215
85. Sriram Ravichandran , Rohith G. Chitrapur, Saurabh Bhawe, Anupam Chakrapani, **Reena Nair**, Mammen Chandy. Systemic Mastocytosis with Associated Clonal Hematological Non-Mast Cell Lineage Disorder (MDS-RCMD): A Difficult Disease to Diagnose and Treat. *J Indian Journal of Hematology and Blood Transfusion*. 2015 DOI 10.1007/s12288-015-0594-2.

#### **Publication –Book Chapters**

1. Advani SH, **Nair R**. Advances in pediatric oncology. In. Gupta S (ed) Recent advances in pediatrics, 1994 pp 301-23.
2. **Nair R**, Advani SH. Acute Leukaemia's. In Manual of Medical Emergencies, published by MM Health Care Pvt. Ltd.1997 pp 388 – 394.
3. **Nair Reena**. Molecular studies in leukemias: Practical Importance. Ixth National CME in Hematology, 2003, by Dr M B Agarwal. Pg 137-146.
4. **Nair Reena**, Advani SH. Acute Leukemias in the Manual of Medical Emergencies, 2nd edition, 2003 pg 600-620.
5. Advani SH, Saikia TK, Gopal R, **Nair Reena** et al. Febrile Neutropenia: Indian Guidelines, Indian Society of Medical & Pediatric Oncology 2004.
6. **Reena Nair**, Sheetal Acute Promyelocytic Leukemia. Hematology Update – 2006. Practical Importance. XIIth National CME in Hematology, 2006, by Dr M B Agarwal.
7. **Reena Nair**, Vikram GS. Mantle cell lymphoma : recent advances in the management. Hematology Update – 2007. Practical Importance. XIIIth National CME in Hematology, 2007, by Dr M B Agarwal.
8. **Reena Nair**, Vikram GS. Follicular lymphoma : Towards Cure. Hematology Update – 2008. Practical Importance. XIVth National CME in Hematology, 2007, by Dr M B Agarwal.

9. **Reena Nair.** Gastric MALT Lymphoma : Towards Cure. Hematology Update – 2009. Practical Importance. XIVth National CME in Hematology, 2008, by Dr M B Agarwal.
10. Sriram Ravichandran, **Reena Nair.** An approach to a patient with Lymphadenopathy: Hematology Update – 2015. Practical Importance. XVth National CME in Hematology, 2015, by Dr M B Agarwal.

**Publications- Conference Papers**

1. Myelodysplastic syndrome: a clinical and pathological analysis of 88 patients. XIV annual conference of Bombay Haematology Group, February, 1990.
2. Myelodysplastic syndrome. Annual conference of Association of physicians of India, January 1991.
3. Modified MACOP-B chemotherapy for intermediate and high grade non-Hodgkin's lymphoma. VII Biennial conference of Indian association of cancer chemotherapists, Ahmedabad, March 1993.
4. Malignant germ cell tumours in childhood. VII Biennial conference of Indian association of cancer chemotherapists, Ahmedabad, March 1993.
5. MACOP-B vs MECOP-B in treatment of intermediate and high grade non Hodgkin's lymphoma. XVI International Cancer Congress, New Delhi October 1994.
6. (a) A prospective controlled study of the prevalence of Barrett's esophagus in cancer chemotherapy recipients, pp XVI. International Cancer Congress, New Delhi, October 1994, pp 441.  
(b) and at Indian Society of Gastroenterology 1995; Cuttack.
7. Results of treatment with MACOP-B and Salvage therapy with MINE in Intermediate - and High- grade Non Hodgkins Lymphoma. ISMPO 1995; Bangalore.
8. All Trans Retinoic Acid and low dose Cytosine Arabinoside in patients with Myelodysplastic syndrome: Results of a pilot study. ISMPO 1995; Bangalore.
9. Non Hodgkins Lymphoma a randomised comparison of efficacy and toxicity of epirubicin versus doxorubicin. 12th Asia Pacific Cancer Conference 1995; Singapore.
10. Retinoic acid syndrome in Acute Promyelocytic Leukemia. 37th Annual Conference, Indian Society of Hematology and Blood Transfusion 1996; Chandigarh.
11. Symposium on "Rationale of Dose Intensive Chemotherapy". 37th Annual Conference, India Society of Hematology and Blood Transfusion 1996; Chandigarh.
12. Mantle Cell Lymphoma, a clinico-pathological study. 38<sup>th</sup> Annual Conference, Indian Society of Hematology and Blood Transfusion 1997; Calcutta.
13. Amifostine in Myelodysplastic Syndrome. Annual Conference, Bombay Hematology and Blood Transfusion February 1998.
14. BCL-2 translocation and expression in follicular and diffuse large B-cell lymphomas in India. IX Meeting European Association for Haematopathology, April 1998, Leiden, The Netherland.
15. Conducting Randomized Clinical Trials in the Developing Countries. Asian Clinical Trials Conference, Hong Kong, October 1998.
16. Pediatric Germ Cell Tumours. Pediatric Hematology Oncology Chapter IAP, Mumbai, December 1998.
17. Chemotherapy Drugs at skill station. Pediatric Hematology Oncology Chapter IAP, Mumbai, December 1998.
18. Conducting Randomized Clinical Trials in a Tertiary Cancer Hospital at ISMPO, Jodhpur, January 1999.
19. Low Grade NHL - controversies in treatment. Symposium on Newer Developments in Hematology at 23<sup>rd</sup> Annual Conference of BHG, Mumbai, February 1999.
20. Acute Promyelocytic Leukemia : All Trans-Retinoic Acid along with Daunomycin followed by Arsenic Trioxide as Sequential Therapy at 23<sup>rd</sup> Annual Conference of BHG, Mumbai, February 1999.
21. Acute Promyelocytic Leukemia : All Trans Retinoic Acid along with Daunomycin Followed by Arsenic Trioxide as Sequential Therapy. (Abs No. 87) ASCO 1999.
22. Role of Amifostine in Patients with Aggressive Myelodysplastic Syndromes, (Leukemia Research. April 1999; Vol 23, Supp1 : Abs No. 206, Pg S78) at Vth Myelodysplastic Syndrome Conference, Prague, Czech Republic, May 1999.

23. Systemic Treatment of Breast Cancer. Workshop on Training of Trainers on Prevention, Early Detection and Treatment of Breast Cancer. Organised by Dept. of Preventive Oncology, September 1999.
24. Quality of Life in Cancer Patients. Symposium titled "Newer Horizons in Supportive Cancer Management" at XXI National Conference, AROI, Calcutta, December 1999.
25. Supportive Oncology Care. Symposium at Bharatpur Cancer Hospital - NEPAL, December 1999.
26. Acute Promyelocytic Leukemia: All Trans Retinoic Acid along with Daunomycin followed by Arsenic Trioxide as sequential therapy. XV Asia Pacific Cancer Conference, Chennai, December 1999.
27. Clinical Survey: The impact of anemia and fatigue on Cancer patients. XV Asia Pacific Cancer Conference, Chennai, December 1999.
28. Role of Amifostine in patients with Aggressive Myelodysplastic Syndromes. XV Asia Pacific Cancer Conference, Chennai, December 1999.
29. Acute Promyelocytic Leukemia : All Trans Retinoic Acid along with Daunomycin followed by Arsenic Trioxide as sequential therapy at 24<sup>th</sup> Annual Conference of Bombay Hematology Group, February 2000.
30. Clinical Survey: The impact of anemia and fatigue on Cancer patients at 24<sup>th</sup> Annual Conference of Bombay Hematology Group, February 2000.
31. Role of Amifostine in patients with Aggressive Myelodysplastic Syndromes at 24<sup>th</sup> Annual Conference of Bombay Hematology Group, February 2000.
32. Acute Promyelocytic Leukemia: All trans retinoic acid along with daunomycin followed by Arsenic trioxide as sequential therapy. 28<sup>th</sup> World Congress of the International Society of Hematology (ISH 2000), Toronto, August 2000.
33. Acute Promyelocytic Leukemia : All Trans Retinoic Acid along with Daunomycin followed by Arsenic Trioxide as Sequential Therapy at Indian Society Medical & Pediatric Oncology, Hyderabad January 2001.
34. Acute Promyelocytic Leukemia : All Trans Retinoic Acid along with Daunomycin followed by Arsenic Trioxide as Sequential Therapy at 11<sup>th</sup> International Congress on Anti Cancer Treatment, Paris, January 2001.
35. Acute Promyelocytic Leukemia : All Trans Retinoic Acid along with Daunomycin followed by Arsenic Trioxide as Sequential Therapy at American Society Cancer , San Francisco **Proc Am Soc Clin Oncol 2001; 20: abstr 1213.**
36. Alternating Triple Therapy (CHOP-MINE-ESHAP) in large cell B phenotype, non Hodgkin's Lymphoma at American Society Cancer, San Francisco **Proc Am Soc Clin Oncol 2001; 20: abstr 1160.**
37. Acute Promyelocytic Leukemia: All trans retinoic acid along with Daunomycin followed by Arsenic trioxide as sequential therapy, at the **Joint International Congress on APL and Differentiation Therapy** at Rome, Italy poster presentation, **Oct 2001.**
38. Alternating Triple Therapy (CHOP-MINE-ESHAP) in large cell B phenotype, non Hodgkin's Lymphoma published in the proceedings of Lymphoma Conference at **Lugano 2002.**
41. Adjuvant Breast Cancer Trial (ABC) and the lessons learnt in conducting an Adjuvant Trial presented at the close out meet NCRI Adjuvant Breast Cancer International Participants Meeting, **London 2004.**
42. Randomized phase II trial of three gemcitabine (GEM) – taxane combinations in Metastatic breast cancer (MBC)(B9E-MC-S197). **ASCO abstract 2004.**
43. Ovarian ablation (OA) in permenopausal women with early breast cancer prescribed 5 years tamoxifen (T) or T plus chemotherapy (CT) – Results from the UK NCRI Adjuvant Breast Cancer (ABC) International trial of 2144 patients. Poster at **ASCO 2004**
44. Polychemotherapy (CT) in pre and post-menopausal women with early breast cancer prescribed 5 years of tamoxifen (T) - Results from the UK NCRI Adjuvant Breast Cancer (ABC) International trial of 1991 patients. Poster at **ASCO 2004**
45. Thromboembolic events (TEC) in Adjuvant Breast Cancer (ABC) International trial –Retrospective and Prospective audit. Poster at **ASCO 2004.**
46. Clonal IgVh dominance of B-CLL cells in response to chemokine SDF1. Poster presented at **IACR (Ind J Med Res 2005).**

47. Selective migration of IgVH3+ B –cell CLL clones in response to chemokine SDF1. Poster at **BSH 2006**
48. To assess the effect of chemotherapy on reactivation of tuberculosis. Poster at **ESMO, Istanbul 2006**
49. Primary thyroid lymphomas. Single center experience. Poster at **ESMO, Istanbul 2006**.
50. Phase III study of temsirolimus with letrozole or letrozole alone in postmenopausal women with locally advanced or metastatic breast cancer. Poster at the **29<sup>th</sup>, Annual San Antonio Breast Cancer Symposium, 2006** (one of the investigators).
51. Prospective study of pattern of IFI and role of latex agglutination in GM and CM antigen detection in patient presenting with HR Neutropenic fever. **JCO 26 : Abstract No – 20534 ; 20 May 2008**
52. Risk factors for poor performance status in cancer patients : A multivariate analysis in 3585 patients. **Proc ASCO 2008; (20: abstr 9628)**.
53. Dr J G Parekh Oration at the 33<sup>rd</sup>, Annual conference of the Mumbai Hematology Group: Acute Promyelocytic Leukemia – A journey from Curse to Cure **2010**.
54. ISHTM HAEMATOCON Conference Kolkatta, Adolescent and Young Adult (AYA) Lymphomas 2010.
55. Phase II feasibility study of combination chemotherapy with fractionated endoxan, vinblastine, oral etoposide and prednisolone in patients with Acquired immunodeficiency syndrome (AIDS) related aggressive lymphomas. ICML, Lugano (abstract: 488) Ann of Oncol 2011; 22 (4): iv 236.
56. Comparison of toxicity and outcomes of BCNU-containing conditioning regimens versus LACE in lymphoma transplants: A retrospective multicenter analysis. Indian Oncology Study Group (IOSG). Poster in **ASH 2011**
57. Cytogenetic analysis helps identification of prognostic groups in Multiple Myeloma: the experience from Ind J Mol Diag 2012; 14 (Abs# 459) pp 667.
58. Retrospective single center analysis of safety, efficacy and toxicity of Rituximab (original) and its biosimilar in diffuse large B cell lymphoma patients treated with chemoimmunotherapy. ESMO Congress, Vienna 2012 (Abstract No 1074P)
59. Predicting response rates of High grade non Hodgkin's lymphomas: a comparative study of International Prognostic Index (IPI) with Subjective Global Assessment. ESMO Congress, Vienna2012 (Abstr No- 106242P)
60. Comparison of efficacy and safety of Rituximab (Mabthera and its biosimilar Reditux), in diffuse large B cell lymphoma patients treated with chemoimmunotherapy: a retrospective analysis. ISHTM 2012, Puri.
61. Sequential Arsenic trioxide and all trans retinoic acid with daunomycin yield early cytogenetic and molecular response in newly diagnosed acute promyelocytic leukemia- Data from a tertiary cancer center. Poster in **ASH 2012**
62. Lateef Zameer, Divya Midha, Manjusha Biswas, **Reena Nair**. Leukemic infiltration of gall bladder, masquerading as symptomatic cholelithiasis, unusual presentation in a known case of Chronic Lymphocytic Leukemia. Poster presented at the RGCON 2014
63. Anupam Chakrapani, Bhave Sourav, Mayur Parihar, Neeraj Arora, Sanjay Bhattacharya, Deepak Mishra , **Reena Nair**, Mammen Chandy. Decitabine as bridge to definitive therapy for Acute Myeloid Leukemia and Myelodysplastic Syndrome: Experience of a tertiary cancer center from India. Oral Presentation at the ACE Meeting Aug 2014, Mumbai
64. Myeloablative Haploidentical Stem Cell Transplantation (PTCy) in Relapse /Refractory Acute Myeloid leukemia: A single center experience. Oral Paper Hematocon 2014, Mumbai 6<sup>th</sup> to 9<sup>th</sup> November.
65. Champa Ghosh, Chandrayee Sarker, Pulak Paik, Sriram Ravichandran, Saurabh Bhave, Anupam Chakrapani, Neeraj Arora, Rimpa Basu, Mammen Chandy, **Reena Nair**. Demography and early treatment outcomes of lymphomas: Prospective EMR data. ISMPO 2015, Mumbai 6<sup>th</sup> to 9<sup>th</sup> Novemeber,
66. Sriram Ravichandran, Neeraj Arora, Indu Arun, Bhave Saurabh Jayant, Anupam Chakrapani, Mammen Chandy, **Reena Nair**. NK/T-cell lymphoma: A reason to SMILE. ISMPO 2015, Mumbai 6<sup>th</sup> to 9<sup>th</sup> Novmeber.
67. Rohith.G.Chitrapur, Sriram Ravichandran,Saurabh Bhave Jayant, Anupam Chakrapani, **Reena Nair**, Mammen Chandy. R-DA-EPOCH in high grade lymphoma- Single center experience. Hematocon 2015, Bangalore 2015 7<sup>th</sup> to 9<sup>th</sup> November.
68. Chandrayee Sarker, Champa Ghosh, Pulak Paik, Neeraj Arora, Sourabh Bhave, Anupam Chakrapani, Rimpa Basu Achari, Mammen Chandy, **Reena Nair**. We too see elderly patients with Lymphoma in our clinics. ISMPO 2015, Mumbai 6<sup>th</sup> to 9<sup>th</sup> November.
69. Patel U, Arun SR, Yadav A, Gore A, Mishra DK, Arora N, Bhattacharya A, Krishnan S, Saha V, Bhave S, Chakrapani A, **Nair R**, Chandy M, Parihar M. Cytogenetic And Molecular Profile Of Acute Myeloid

Leukemia (AML) From A Tertiary Care centre In Eastern India. Hematocon 2015, Bangalore 2015 7<sup>th</sup> to 9<sup>th</sup> November.

**Awards – during my college days**

1.	Laxmibai Korane prize for standing first in Goa Medical college, Ist MB,BS.
2.	Goa Medical College First Prize in Human Anatomy, for proficiency at MB,BS, university examinations

**Orations**

S.No	Year	Topic and meeting
1.	2010	Acute Promyelocytic Leukemia – A journey form Curse to Cure. Dr JG Parekh Oration at the 33 <sup>rd</sup> , Annual Conference of the Mumbai Hematology Group.
2.	2011	Clinical Trials- Facts and Myths. Advances in Science, Engineering and Technology (ASET) colloquia, Tata Institute of Fundamental Research, Mumbai.

**Awards – during my tenure as convener Hematolo-Lymphoid (Adult) DMG, TMH, Mumbai 2009- 2012**

S.No	Year	Topic and meeting
1.	2010	2 <sup>nd</sup> , Prize for Oral Presentation-Adolescent and Young Adult (AYA), lymphomas. (Reena Nair) ISHTM HAEMATOCON Conference, Kolkatta
2.	2011	1 <sup>st</sup> , Prize for Oral Presentation- Long Term Outcomes of Bone Marrow Transplantation in Multiple Myeloma. (Bhausahab Bagal) Mumbai Hematology Group 35 <sup>th</sup> Annual Meet.
3.	2012	1 <sup>st</sup> , Prize for Oral Presentation - A phase II feasibility study of combination therapy with fractionated cyclophosphamide, vinblastine, oral etoposide and prednisolone in patients with Acquired Immunodeficiency Syndrome (AIDS) related aggressive lymphomas. (Manju Sengar). Lymphoma and Leukemia 2012 (ESO), Mumbai.
4.	2012	3 <sup>rd</sup> , Prize for Oral Presentation – SMILE for peripheral T cell lymphoma- an effective and safe regimen. (Seema Gulia). Lymphoma and Leukemia 2012 (ESO).
5.	2012	1 <sup>st</sup> , Prize for Poster Presentation- CD 200 expression in lymphoid cells of non Hodgkin's lymphomas involving the bone marrow and peripheral blood.(Neha Mittal). Lymphoma and Leukemia 2012 (ESO).
6.	2012	3 <sup>rd</sup> , Prize for Poster Presentation – Dasatinib in second line treatment for Chronic Myeloid leukemia- a single centre experience. (Shilpa Gupta). Lymphoma and Leukemia 2012
7.	2012	1 <sup>st</sup> Prize for Poster Presentation - Predicting early outcomes of non Hodgkin's lymphoma: A comparative study of International Prognostic Index (IPI) with Subjective Global Assessment (SGA). (Vikas Ostwal) Mumbai Hematology Group 36 <sup>th</sup> Annual Meet.
8.	2012	2 <sup>nd</sup> , Prize for Oral Presentation – Phase II feasibility study of Oral Metronomic chemotherapy-ME2C in adult patients with relapsed/refractory High grade B cell Non-Hodgkin's lymphoma not eligible for stem cell transplantation. (Ravi Thippeswamy) Mumbai Hematology Group 36 <sup>th</sup> Annual Meet.